Ongoing trials in low-grade lymphoma

• Main Author: Alexander Burchardt
• Format: Article
• Language: English
• Published: PAGEPress Publications 2011-10-01
• Series: Hematology Reports
• Subjects: low-grade lymphoma, treatment, rituximab, non-pegylated liposomal doxorubicin, bendamustine.
• Online Access: http://www.pagepress.org/journals/index.php/hr/article/view/3872

There are many therapies available for the management of low-grade lymphoma. With follicular lymphoma, for example, combination of chemotherapy and rituximab (immuno-chemo - therapy) and consecutive maintenance therapy for 2 years is the current standard of care. To date, the most widely used regimen seems to be rituximab combined with cyclo phosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Substitution of liposomal doxorubicin in place of conventional doxorubicin may improve outcomes in this indication, although evidence for its use in low-grade lymphoma is not as relevant as in aggressive lymphoma. Bendamustine, in combination with rituximab, has shown very good efficacy and tolerability in several lymphoma types, particularly follicular lymphoma and other low-grade lymphomas. Other combinations, such as those including bortezomib and lenalidomide, are under investigation in low-grade lymphoma, and the duration of rituximab maintenance therapy following bendamustine−rituximab-containing induction is being researched by the German Study Group for Indolent Lymphoma (StiL).